Regeneron Pharmaceuticals founder and CEO Leonard Schleifer said the U.S. entrepreneurial spirit and constitutional protections enabled the company's legacy of innovation.
This perspective highlights the intersection of legal frameworks and scientific advancement, suggesting that commercial stability is a prerequisite for high-risk medical research.
Speaking on June 8, 2026, Schleifer reflected on the environment that supports pharmaceutical growth. He said the tradition of innovation in the United States creates a unique ecosystem for companies to thrive. This culture allows for the transition of scientific discovery into viable commercial products.
Schleifer pointed to the role of the U.S. Constitution in safeguarding intellectual property. He said that constitutional patent protections are approximately 250 years old [1]. These protections, he said, provide the necessary security for firms to invest in long-term research and development.
According to Schleifer, the ability to protect inventions ensures that the risks associated with drug development are balanced by the potential for reward. This balance fosters an environment where scientists can pursue breakthroughs without the immediate threat of losing their intellectual property to competitors.
Regeneron has utilized these frameworks to build its current standing in the pharmaceutical industry. Schleifer said the company's growth is a direct result of this broader national commitment to entrepreneurship, and the legal protections that accompany it.
The discussion emphasized that while scientific talent is global, the specific legal and cultural infrastructure of the U.S. provides a distinct advantage for scaling biotech firms. Schleifer said this combination of spirit and law is what drives the industry forward.
“Constitutional patent protections are approximately 250 years old”
The emphasis on 250-year-old patent laws underscores a long-standing debate in the science industry regarding the balance between intellectual property rights and public access to medicine. By linking Regeneron's success to constitutional protections, Schleifer argues that the legal ability to monopolize an invention for a set period is the primary engine for the expensive, high-failure-rate process of drug discovery.
